Advances on the treatment of Dyslipidaemias

Advances on the treatment of Dyslipidaemias

Treatment targets for Low Density Lipoprotein Cholesterol (LDL-C), according to the recently published guidelines, are low enough and a substantial proportion of patients are unable to reach them. A new class of hypolipidaemic medications, proprotein convertase subtilisin/kexin type 9 inhibitors (PC...

Full description

Bibliographic Details
Main Author:	Eleni Bilianou
Format:	Article
Language:	ell
Published:	Scientific Council of the General Hospital of Piraeus Tzaneion 2017-01-01
Series:	Epistīmonika Chronika
Subjects:	PCSK9 inhibitors LDL-C Dyslipidaemias
Online Access:	http://www.tzaneio.gr/images/docs/S1-15.pdf

Similar Items

Role of PCSK9 inhibitors in the management of dyslipidaemia
by: Tiny Nair
Published: (2024-03-01)

New Therapeutic Approaches in Treatment of Dyslipidaemia—A Narrative Review
by: Iveta Merćep, et al.
Published: (2022-07-01)

A Systematic Approach to Assess the Activity and Classification of PCSK9 Variants
by: Kepa B. Uribe, et al.
Published: (2021-12-01)

Update on the Management of Diabetic Dyslipidaemia
by: Iciar Martín-Timón, et al.
Published: (2018-11-01)

Effects of evolocumab therapy and low LDL‐C levels on vitamin E and steroid hormones in Chinese and global patients with type 2 diabetes
by: Dirk J. Blom, et al.
Published: (2020-04-01)

Genetics in familial hypercholesterolaemia – from genetic research to new guidelines
by: Edyta Kinga Prokop, et al.
Published: (2019-04-01)

PCSK9: BIOLOGICAL ACTIVITY REGULATION AND CONNECTION WITH LIPID AND CARBOHYDRATE METABOLISM
by: A O Averkova
Published: (2017-09-01)

PCSK9 Inhibitor Therapy as an Alternative for Statin Intolerance
by: K. O. Shnaider, et al.
Published: (2023-12-01)

Low-density lipoprotein particles in atherosclerosis
by: Ya-Nan Qiao, et al.
Published: (2022-08-01)

Low-density lipoprotein cholesterol lowering treatment: the current approach
by: Irina Crismaru, et al.
Published: (2020-05-01)

Is lower better? Is lowest the best?
by: Lale Tokgözoğlu
Published: (2017-04-01)

Management of High-Risk Hypercholesterolemic Patients and PCSK9 Inhibitors Reimbursement Policies: Data from a Cohort of Italian Hypercholesterolemic Outpatients
by: Federica Fogacci, et al.
Published: (2022-08-01)

Rare primary dyslipidaemias associated with low LDL and HDL cholesterol values in Portugal
by: Ana Catarina Alves, et al.
Published: (2023-04-01)

Supplementation with Octacosanol Affects the Level of PCSK9 and Restore Its Physiologic Relation with LDL-C in Patients on Chronic Statin Therapy
by: Milica Zrnic Ciric, et al.
Published: (2021-03-01)

Efficacy and safety of tafolecimab in Chinese patients with heterozygous familial hypercholesterolemia: a randomized, double-blind, placebo-controlled phase 3 trial (CREDIT-2)
by: Meng Chai, et al.
Published: (2023-02-01)

Serum sdLDL-C and cellular SREBP2-dependent cholesterol levels: Is there a challenge on targeting PCSK9?
by: Soltanmohammadi Elham, et al.
Published: (2016-01-01)

Current treatment of dyslipidaemia: PCSK9 inhibitors and statin intolerance
by: Konstantinos Koskinas, et al.
Published: (2016-07-01)

Patterns of Dyslipidaemia in Prehypertensive and Normotensive Subjects
by: Usman Wali
Published: (2015-03-01)

Effect of proprotein convertase subtilisin/kexin type 9 inhibition on cancer events: A pooled, post hoc, competing risk analysis of alirocumab clinical trials
by: Kusha A. Mohammadi, et al.
Published: (2023-08-01)

A retrospective nationwide analysis of evolocumab use in Sweden and its effect on low-density lipoprotein cholesterol levels
by: Maria K. Svensson, et al.
Published: (2024-01-01)

Research progress on alternative non-classical mechanisms of PCSK9 in atherosclerosis in patients with and without diabetes
by: Ying Tang, et al.
Published: (2020-03-01)

PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab
by: Blom DJ, et al.
Published: (2016-05-01)

Prevalence and Impact of Apolipoprotein E7 on LDL Cholesterol Among Patients With Familial Hypercholesterolemia
by: Hayato Tada, et al.
Published: (2021-04-01)

Retargeting the management of hypercholesterolemia – focus on evolocumab
by: Colletti A, et al.
Published: (2016-09-01)

Clinical efficacy and safety of evolocumab for low-density lipoprotein cholesterol reduction
by: Henry CA, et al.
Published: (2016-04-01)

The pattern of dyslipidaemia and factors associated with elevated levels of non-HDL-cholesterol among patients with type 2 diabetes mellitus in the Ho municipality: A cross sectional study
by: Sylvester Yao Lokpo, et al.
Published: (2022-08-01)

Pharmacological Options in Atherosclerosis: A Review of the Existing Evidence
by: Keshav Kumar Gupta, et al.
Published: (2018-12-01)

Correlation of PCSK9 and Serum sdLDL Levels and Other Demographic and Laboratory Indicators in Healthy Individuals
by: Reza Hosseini-Fard, et al.
Published: (2018-05-01)

Efficacy and safety of alirocumab in Korean patients with hypercholesterolemia and high cardiovascular risk: subanalysis of the ODYSSEY-KT study
by: Chang-Wook Nam, et al.
Published: (2019-11-01)

Prevalence, self-awareness, and LDL cholesterol levels among patients highly suspected as familial hypercholesterolemia in a Japanese community
by: Hayato Tada, et al.
Published: (2020-11-01)

Inhibition of PCSK9 does not improve lipopolysaccharide-induced mortality in mice
by: Jean-Mathieu Berger, et al.
Published: (2017-08-01)

Nutraceuticals for the Control of Dyslipidaemias in Clinical Practice
by: Peter E. Penson, et al.
Published: (2021-08-01)

Neoagarooligosaccharides enhance the level and efficiency of LDL receptor and improve cholesterol homeostasis
by: Ji Hye Yang, et al.
Published: (2017-11-01)

PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile in Subjects at High or very High Cardiovascular Risk
by: Pere Rehues, et al.
Published: (2023-01-01)

Pharmaco-invasive therapy: Early implementation of statins and proprotein convertase subtilisin/kexin type 9 inhibitors after acute coronary syndrome
by: F. B. Mensink, et al.
Published: (2022-12-01)

The N‐Acetylgalactosamine‐conjugated small interfering RNA inclisiran can be coadministered safely with atorvastatin in cynomolgus monkeys resulting in additive low‐density lipoprotein cholesterol reductions
by: Dario Lehoux, et al.
Published: (2023-04-01)

Treatment of Dyslipidaemia in Children
by: Riccardo Fiorentino, et al.
Published: (2021-08-01)

Antiplatelet Effects of PCSK9 Inhibitors in Primary Hypercholesterolemia
by: Piotr Pęczek, et al.
Published: (2021-05-01)

Editorial: Genetics of familial hypercholesterolemia: New insight—Volume II
by: Alpo Vuorio, et al.
Published: (2022-10-01)

Editorial: Genetics of Familial Hypercholesterolemia: New Insight
by: Alpo Vuorio, et al.
Published: (2021-05-01)